drugset / Trial / NCT04246502
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, multicenter phase 2 clinical trial to evaluate the efficacy and safety of capecitabine plus pyrotinib versus capecitabine plus trastuzumab plus pertuzumab in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.
Timeline
- Start
- 2020-01
- Primary completion
- 2022-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pertuzumab | Monoclonal antibody | — | — |
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |
| Comparator | Trastuzumab | Monoclonal antibody | — | — |
| Comparator | Capecitabine | Small molecule | — | — |